Trusted Resource for Clinical Trials, Protocols & Progress
Managing amendments effectively is essential for maintaining compliance in UK clinical trials. By distinguishing between substantial and non-substantial changes, following MHRA and HRA submission pathways, and keeping robust documentation, sponsors and investigators can navigate amendments smoothly. Strong planning and communication are key to avoiding inspection findings and ensuring trial continuity.
Click to read the full article.
Pharmacovigilance obligations in the UK clinical trial context are strict, comprehensive, and non-negotiable. Sponsors must establish robust systems for SAE/SUSAR reporting, DSUR submission, urgent safety measures, and oversight of CROs. By aligning with MHRA, HRA, and international standards, sponsors can ensure participant safety, regulatory compliance, and inspection readiness throughout clinical development.
Click to read the full article.
CROs are essential partners in UK clinical research, bridging regulatory, operational, and logistical challenges. While they bring expertise in monitoring, data management, and pharmacovigilance, ultimate accountability rests with sponsors. Clear delegation, strong oversight, and proactive collaboration with CROs ensure compliance with MHRA, HRA, and ICH E6(R2) standards while enabling trials to progress efficiently within the NHS and academic landscape.
Click to read the full article.
NHS Trusts are at the heart of the UK’s clinical research ecosystem, providing access to diverse patient populations and delivering high-quality data. By adopting best practices in governance, inspection readiness, workforce development, and digital integration, Trusts can strengthen their role as world-class clinical trial sites. Collaboration with sponsors, CROs, and NIHR CRN is key to maximising trial success and ensuring patient-centric research outcomes.
Click to read the full article.
Data integrity issues remain a top focus of MHRA inspections in UK clinical trials. By understanding common pitfalls, addressing root causes, and adopting robust oversight mechanisms, sponsors, CROs, and NHS Trusts can safeguard trial credibility. A proactive, problem–solution approach ensures that data remain reliable, regulatory-compliant, and fit for global submissions.
Click to read the full article.
UK clinical trial transparency obligations post-Brexit are evolving toward a more independent system, while still aligned with global expectations. Sponsors must manage fragmented registry requirements, stricter enforcement by HRA, and the need for plain language communication. Early planning, strong CRO support, and proactive dialogue with regulators are essential to maintain compliance and public confidence in the UK research environment.
Click to read the full article.
Expanded access and compassionate use programmes in the UK provide vital treatment options for patients who cannot enrol in trials. With frameworks such as EAMS and named patient supply, MHRA and HRA ensure that patient safety and ethical standards are maintained. Sponsors, CROs, and NHS Trusts must work together to overcome administrative challenges, integrate safety data, and maintain transparency. These programmes not only provide immediate patient benefit but also strengthen the evidence base for regulatory decision-making.
Click to read the full article.
Post-marketing surveillance trials in the UK are essential for maintaining medicine safety and public trust beyond the point of authorisation. With MHRA oversight, HRA ethical governance, and NHS infrastructure, PMS studies generate crucial evidence for long-term safety, effectiveness, and real-world application. Sponsors, CROs, and investigators must adopt best practices in trial design, pharmacovigilance integration, and data quality management to meet regulatory expectations. As the UK advances its independent framework post-Brexit, PMS trials will continue to shape both patient safety outcomes and healthcare policy decisions.
Click to read the full article.
Decentralized clinical trials in the UK reflect a broader shift toward patient-centric research and digital innovation. MHRA guidance encourages adoption while reinforcing GCP, data integrity, and patient safety. Sponsors, CROs, and NHS Trusts must carefully plan, validate, and document DCT elements to remain inspection-ready. By balancing flexibility with regulatory compliance, decentralized trials can expand access, reduce participant burden, and strengthen the UK’s role in global clinical research.
Click to read the full article.
Phase 3 global trials in the UK highlight both the strengths and challenges of conducting large-scale research within the NHS framework. While MHRA oversight ensures robust compliance, recurring issues such as TMF quality, SAE reporting delays, and recruitment bottlenecks demand ongoing sponsor attention. Case studies from oncology, cardiovascular, rare disease, and vaccine trials demonstrate the importance of early planning, NIHR integration, and proactive regulatory engagement. By applying lessons learned from past experiences, sponsors and CROs can strengthen the UK’s position as a reliable hub for global Phase 3 development.
Click to read the full article.
